The neutrophil-lymphocyte ratio (NLR) is an established signature of inflammation used for evaluating renal cell carcinoma (RCC).
To determine the utility of NLR and its relationship with known risk factors associated with poor survival in patients with metastatic RCC and tumor thrombus undergoing cytoreductive nephrectomy (CN).
Prognostic variables were reviewed for patients undergoing CN with thrombectomy between 2000 and 2014 from six different institutions. Patients were stratified for NLR >4.0 based on cut point analysis.
Kaplan-Meier curves compared overall survival of the total cohort and established risk models (Memorial Sloan Kettering Cancer Center [MSKCC], International Metastatic Renal-Cell Carcinoma Database Consortium [IMDC], and M.D. Anderson Cancer Center [MDACC]) stratified by NLR. Multivariable Cox regression determined predictors of overall survival. Receiver operator characteristic curves tested the predictive accuracy of survival ≥12 mo, and area under the curve (AUC) was compared between models.
In total, 332 patients were identified. Patients with NLR ≤4.0 had longer median survival (24.7 vs 15.2 mo, p=0.004). NLR >4.0 distinguished patients with significantly shorter survival for non-poor-risk groups defined by MSKCC, IMDC, and MDACC criteria. Systemic symptoms, low hemoglobin, elevated lactate dehydrogenase, retroperitoneal adenopathy, level IV thrombus, elevated absolute neutrophil count, and NLR >4 were independent predictors of decreased survival (p<0.05). These factors had higher predictive accuracy for survival at 12 mo (AUC=0.755) than MKSCC, IMDC, and MSKCC models.
NLR >4.0 independently predicts poor survival and further distinguishes established risk model survival curves. We identified seven preoperative risk factors related to poor survival for patients with metastatic RCC with tumor thrombus undergoing CN.
The neutrophil-lymphocyte ratio and six additional preoperative variables can be used to better council patients regarding survival after surgery for metastatic renal cell carcinoma with tumor thrombus.
European urology focus. 2018 Sep 08 [Epub ahead of print]
Charles C Peyton, E Jason Abel, Juan Chipollini, David C Boulware, Mounsif Azizi, Jose A Karam, Vitaly Margulis, Viraj A Master, Surena F Matin, Jay D Raman, Wade J Sexton, Christopher G Wood, Philippe E Spiess
Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. Electronic address: ., University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA., University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., University of Texas Southwestern Medical Center, Dallas, TX, USA., The Emory Clinic, Atlanta, GA, USA., Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.